Characterization of several leukemia‐associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia

To design a specific immunotherapy for leukemia patients, the identification of leukemia‐associated antigens (LAAs) is a pivotal step. Antileukemic effects after hematopoetic stem cell transplantation for myeloid leukemias are observed and might be related to the recognition of LAAs. Using the serological screening of an expression library (SEREX) of K562 cells, we identified 16 different clones encoding LAAs eliciting a humoral immune response, among them the heat shock proteins HSJ2 and HSP70, the M‐phase phosphoprotein 11 (MPP11), the BRCA1‐associated protein (BRAP), the Jκ recombination binding protein (RBPJκ) and the receptor for hyaluronic acid mediated motility (RHAMM). Serological responses to MPP11 were observed in 7/19 (37%) of patients with acute myeloid leukemia (AML) and 6/16 (38%) of patients with chronic myeloid leukemia (CML), but not in healthy volunteers (0/20). IgG antibodies directed against MPP11 were also detected in 25–50% of the sera of patients with solid tumors such as melanoma, renal cell, ovarian and breast carcinoma. mRNA expression of MPP11 was detected in 20/20 AML patients and 7/10 patients with CML. In normal tissues, strong mRNA expression of MPP11 was only detected in testis. By real‐time PCR, we detected upregulation of MPP11 in leukemic blasts. Simultaneous humoral immune responses to 2 or more of the 16 LAAs identified here was observed, suggesting the feasibility of a polyvalent vaccination as an option for immunotherapies in leukemia patients. © 2003 Wiley‐Liss, Inc.

[1]  Wen-Hwa Lee,et al.  Identification of a Novel Cytoplasmic Protein That Specifically Binds to Nuclear Localization Signal Motifs* , 1998, The Journal of Biological Chemistry.

[2]  R. Soiffer.  Donor lymphocyte infusions: the door is open. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  U. Maurer,et al.  Wilms tumor gene (wt1) mRNA is equally expressed in blast cells from acute myeloid leukemia and normal CD34+ progenitors. , 1997, Blood.

[4]  W. Shoji,et al.  MIDA1, an Id-associating protein, has two distinct DNA binding activities that are converted by the association with Id1: a novel function of Id protein. , 1999, Biochemical and biophysical research communications.

[5]  L. Norton,et al.  BRCA-associated breast cancer in young women. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Patel,et al.  MAZ, a zinc finger protein, binds to c-MYC and C2 gene sequences regulating transcriptional initiation and termination. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[7]  W. M. Smit,et al.  Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. , 1999, Blood.

[8]  S. Faderl,et al.  Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells , 1995, British journal of haematology.

[9]  D. Jäger,et al.  Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[10]  I. Pollack,et al.  Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity. , 2000, Cancer research.

[11]  E. Craig,et al.  Zuotin, a ribosome‐associated DnaJ molecular chaperone , 1998, The EMBO journal.

[12]  M. Skolnick,et al.  BRCA1 mutations in primary breast and ovarian carcinomas. , 1994, Science.

[13]  W. Ollier,et al.  Positive selection in autoimmunity: Abnormal immune responses to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis , 1995, Nature Medicine.

[14]  U. Maurer,et al.  High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. , 1997, Blood.

[15]  M. Davis,et al.  A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. , 1999, Cancer research.

[16]  Y. Tamura,et al.  Immunotherapy using heat-shock protein preparations of leukemia cells after syngeneic bone marrow transplantation in mice. , 2001, Blood.

[17]  D. Neuberg,et al.  Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. , 2000, The Journal of clinical investigation.

[18]  M. Baccarani,et al.  Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. , 2001, Blood.

[19]  High Levels of Wilms' Tumor Gene (wt1) mRNA in Acute Myeloid Leukemias Are Associated With a Worse Long-Term Outcome , 1997 .

[20]  S. H. Lim,et al.  Prevalence of antibodies against proteins derived from leukemia cells in patients with chronic myeloid leukemia. , 1998, Blood.

[21]  D. Porter,et al.  Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. , 1996, Bone marrow transplantation.

[22]  U. Maurer,et al.  Simultaneous expression of different immunogenic antigens in acute myeloid leukemia. , 2000, Experimental hematology.

[23]  G N Shah,et al.  Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[24]  P. Hieter,et al.  A putative oncogenic role for MPP11 in head and neck squamous cell cancer. , 2000, Cancer research.

[25]  Yao-Tseng Chen,et al.  Characterization of human colon cancer antigens recognized by autologous antibodies , 1998, International journal of cancer.

[26]  D. Porter,et al.  Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. , 1994, The New England journal of medicine.

[27]  D. Jäger,et al.  Antigens recognized by autologous antibody in patients with renal‐cell carcinoma , 1999, International journal of cancer.

[28]  M. Pfreundschuh,et al.  Serological identification of human tumor antigens. , 1997, Current opinion in immunology.

[29]  W. Wilmanns,et al.  Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. , 1990, Blood.

[30]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[31]  H. Döhner,et al.  Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. , 2002, Experimental hematology.

[32]  W. Shoji,et al.  MIDA1 is a sequence specific DNA binding protein with novel DNA binding properties , 2000, Genes to cells : devoted to molecular & cellular mechanisms.

[33]  M. Lotze,et al.  Immunization with an antigen identified by cytokine tumor vaccine-assisted SEREX (CAS) suppressed growth of the rat 9L glioma in vivo. , 2001, Cancer research.

[34]  K. Itakura,et al.  Genomic Organization and Expression of a Human Gene for Myc-associated Zinc Finger Protein (MAZ)* , 1998, The Journal of Biological Chemistry.

[35]  M J O'Hare,et al.  Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression. , 2001, Cancer immunity.

[36]  M. Dragunow,et al.  Environmental enrichment inhibits spontaneous apoptosis, prevents seizures and is neuroprotective , 1999, Nature Medicine.

[37]  P. Kantoff,et al.  CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Goldman,et al.  Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission , 2000 .

[39]  Robert H. Collins,et al.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  W. Shoji,et al.  MIDA1, a Protein Associated with Id, Regulates Cell Growth (*) , 1995, The Journal of Biological Chemistry.

[41]  A Ferrant,et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.

[42]  K. Parker,et al.  Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. , 1996, Blood.